Njira Lugogo, MD, from University of Michigan.

Tezepelumab Reduces Severe Asthma Exacerbations by 70% in Phase 4 PASSAGE

Real-world phase 4 PASSAGE data presented at the 2

026 American Thoracic Society (ATS) International Conference 

in Orlando, Florida, found that tezepelumab (Tezspire) reduced severe asthma exacerbations by 70%. The treatment also improved disease control across a diverse population of patients with severe uncontrolled 

, including groups routinely excluded from or underrepresented in pivotal trials.

 at ATS 2026, Njira Lucia Lugogo, MD, clinical professor of medicine in the Division of Pulmonary and Critical Care Medicine at the University of Michigan, discussed the implications of the data for real-world prescribing and the need for more inclusive trial design going forward.

PASSAGE Study Design: Real-World Severe Asthma Cohort

PASSAGE was a phase 4, multicenter, single-arm, open-label study enrolling patients aged ≥ 12 years with severe asthma and ≥ 2 exacerbations in the prior year. The 286-patient cohort was intentionally designed to reflect populations underrepresented in randomized controlled trials: 42% had blood eosinophil counts (BEC) ≥ 300 cells/µL, 58% had a positive allergy status, 22% were Black or African American, 7% were adolescents, 20% had comorbid COPD, and 29% were current or former smokers.

Tezepelumab Reduced Annualized Asthma Exacerbation Rate by 70% Overall

The annualized asthma exacerbation rate (AAER) decreased by 70% (95% CI: 63 to 75) from baseline to the treatment period overall. Across asthma phenotypes and underrepresented subgroups, reductions ranged from 54% to 77%, indicating consistent benefit regardless of eosinophil status, smoking history, or comorbid COPD.

"When we scaled up from the very homogeneous clinical trial population to a real-world population, we are replicating the effects and maybe even seeing more profound exacerbation reduction, which is very reassuring," Lugogo told 

. "It should give us the confidence that we can use these drugs in clinical practice successfully."

Tezepelumab Improved FEV1, with Greater Gains in Patients with Impaired Lung Function

At week 52, the least-squares mean change in pre-bronchodilator FEV1 from baseline was 0.12 L (95% CI: 0.07 to 0.17) overall (n = 222). Among patients with baseline FEV1 ≤ 80% predicted — those with the most compromised lung function at enrollment — the improvement was greater, at 0.21 L (95% CI, 0.15 to 0.28; n = 138).

Clinically Meaningful Improvements in Asthma Control and Quality of Life

Clinically meaningful improvements from baseline, defined by minimum clinically important difference thresholds, were observed at week 52 across three validated instruments. Among the overall population (all n = 219), 74% achieved meaningful improvement on the Asthma Control Questionnaire-6 (ACQ-6), 63% on the Asthma Impairment and Risk Questionnaire (AIRQ), and 80% on the St. George's Respiratory Questionnaire (SGRQ). Across asthma phenotypes and underrepresented populations, response rates ranged from 64 to 86% for ACQ-6, 51 to 75% for AIRQ, and 63 to 91% for SGRQ.

Tezepelumab Efficacy in Black/African American Patients with Severe Asthma

Black and African American patients comprised 22% of the PASSAGE cohort, which is a proportion greater than what is typically seen in phase 3 severe asthma trials. Lugogo noted that this population responded well to tezepelumab without new safety signals and framed the findings in the context of a broader access gap.

"Many biologic-eligible patients are simply not receiving any biologic, so I'm hoping that this new data…is going to give us more confidence, and we'll be able to increasingly use biologics in wider patient populations,” Lugogo said.

Tezepelumab Safety Profile Consistent With Prior Trial Data

In total, 28 patients (9.8%) experienced a serious adverse event during the treatment period following tezepelumab initiation. Adverse events were consistent with the established safety profile of the drug.

PASSAGE Highlights Gaps in Severe Asthma Trial Design

Beyond the clinical findings, Lugogo called for a broader reconsideration of how severe asthma trials are structured. Patients with comorbid asthma-COPD overlap remain ineligible for most interventional trials, leaving clinicians without prospective evidence until post-authorization studies like PASSAGE are completed.

"We need to think about whether we need a paradigm shift in how we design our trials to include some of these comorbid populations so that we can have data a bit earlier and not have to wait for data generation afterwards,” Lugogo said.

Watch part 1 of our interview with Lugogo here: 

Tezepelumab Reduced Severe Asthma Across Phenotypes in Phase 4 PASSAGE.

Editor’s note: Relevant disclosures for Lugogo include GlaxoSmithKline, GENZYME CORPORATION, SANOFI-AVENTIS U.S., AstraZeneca Pharmaceuticals, Regeneron Pharmaceuticals, Incyte Corporation, and more.

Lugogo NL, Akuthota P, Sumino K, et al. (

) Tezepelumab in diverse real-world patients with severe asthma across different phenotypes and underrepresented populations: final results from the US phase 4 PASSAGE study. Late-breaking research was presented at the American Thoracic Society 2026 International Conference on May 18 in Orlando, Florida.

Videos

Phase 4 PASSAGE data from ATS 2026 show tezepelumab reduced exacerbation rates across a diverse real-world cohort, including smokers, adolescents, and patients with comorbid COPD.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Abigail Brooks is a strategic content lead overseeing 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The twiist™ Automated Insulin Delivery (AID) system significantly improved glycemic control over 13 weeks in adults with insulin-treated 

, with no severe hypoglycemia events reported, according to trial data presented at the 

2026 Scientific Sessions of the American Diabetes Association (ADA)

“We saw meaningful glycemic improvement from Day 1 in glucose levels that was sustained through 13 weeks, with no severe hypoglycemic events. For people with insulin-treated type 2 diabetes, achieving better control without added risk of lows (hypoglycemia) is a meaningful step forward," said Carol Levy, MD, Professor of Medicine, Mount Sinai Diabetes Center Icahn School of Medicine at Mount Sinai.

Type 2 diabetes represents the largest population of adults on insulin therapy in the US, yet has historically had the fewest AID options available. The 2026 ADA Standards of Care now designate AID as the preferred insulin delivery method over multiple daily injections, continuous subcutaneous insulin infusion, and sensor-augmented pumps for adults with type 2 diabetes on insulin, marking the first time AID has received the highest-grade recommendation for this population.

The twiist-T2D trial represents Sequel Med Tech's first pivotal data in type 2 diabetes and adds to a growing body of evidence supporting AID deployment in this historically underserved population.

The single-arm, multicenter trial, led by Carol Levy, MD, a professor of medicine at the Icahn School of Medicine at Mount Sinai, enrolled 307 adults with insulin-treated type 2 diabetes across 30 US sites.¹ Among the cohort, the mean age was 58 years (range 19–85), 47% of participants were female, the mean was BMI 34 kg/m², the mean diabetes duration 19 years, and 26% of patients were Black or African American and 13% were Hispanic. Participants included both basal-only and basal-bolus insulin users, and 93% (n = 286) completed the 13-week study visit.

Results showed mean HbA1c improved by 0.7 percentage points from a baseline of 8.1% (95% CI, −0.9 to −0.6; 

<.001), with the greatest improvements observed in participants with the highest baseline HbA1c.¹ Mean time in the target glucose range of 70 to 180 mg/dL increased from 57% to 73%, an absolute gain of 16 percentage points (95% CI, 14 to 18; 

<.001), equivalent to nearly 4 additional hours per day in range.¹

The safety profile was favorable, with no severe hypoglycemia events occurring during the trial period.¹ Time below 70 mg/dL decreased from 0.66% at baseline to 0.36% at 13 weeks, and time below 54 mg/dL remained unchanged at 0.02%. A single case of diabetic ketoacidosis was reported but was determined to be unrelated to the device. A total of 14 serious adverse health events were reported, with none attributable to the study device.¹

Glycemic benefits were consistent across clinically relevant subgroups, including users and non-users of metformin, GLP-1 RAs, and SGLT2 inhibitors.¹ Patient-reported outcomes showed improvements in both treatment satisfaction and sleep quality.

“For people with type 2 diabetes who depend on insulin, progress has too often meant more: more decisions, more complexity, more to manage," said Joanna Mitri, Chief Medical Officer of Sequel. "We think it's time to change that. This isn't about asking more of the person; it's about the technology taking on more of the work, so care becomes more personal, more practical, and less demanding, without observing any increased risk of hypoglycemia. These data are an important step in building the evidence it takes to bring that kind of progress to a population that's been underserved for far too long.”

These findings arrive in the context of a rapidly expanding evidence base for AID in type 2 diabetes. A randomized controlled trial published in the 

 found that AID reduced HbA1c by 0.9 percentage points versus 0.3 percentage points in the control group over 13 weeks in insulin-treated adults with type 2 diabetes.

A separate pivotal trial of the Omnipod 5 system in 305 adults with type 2 diabetes showed time in range improve from 45% to 66% and HbA1c decrease from 8.2% to 7.4% over 13 weeks, including in a subgroup of 164 participants concurrently using GLP-1 RAs.

The 2026 ADA Standards of Care removed C-peptide and autoantibody requirements as barriers to AID access, reinforcing that insulin use, not diabetes type, should guide eligibility. This guideline shift has direct implications for how clinicians approach AID prescribing in insulin-treated type 2 diabetes.

The twiist AID system remains investigational for type 2 diabetes and is not currently FDA-cleared for this indication; it is cleared for type 1 diabetes in patients ≥ 6 years of age.¹

Sequel Med Tech. Sequel presents pivotal trial of the twiist™ Automated Insulin Delivery System in adults with insulin-treated type 2 diabetes at the ADA 86th Scientific Sessions. Published June 8, 2026. Accessed June 8, 2026. 

https://www.globenewswire.com/news-release/2026/06/08/3307938/0/en/

Randomized trial of automated insulin delivery in type 2 diabetes. 

American Diabetes Association. Standards of Care in Diabetes — 2026. 

Articles

The twiist automated insulin delivery system produced rapid, sustained glycemic improvement over 13 weeks in insulin-treated adults with type 2 diabetes, with a favorable safety profile. In a 307-participant, multicenter single-arm study, HbA1c fell 0.7 points from 8.1% and time-in-range rose 16 points to 73%, approximating four additional hours daily. No severe hypoglycemia occurred, time-below-range decreased, and a single DKA event was deemed unrelated. Benefits were consistent across adjunctive antihyperglycemic therapies, alongside improved satisfaction and sleep.

twiist improved time in range by 16 percentage points and reduced HbA1c by 0.7 points over 13 weeks in insulin-treated adults with type 2 diabetes, with no severe hypoglycemia events.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 2 Diabetes

twiist AID System Improves HbA1c, Time in Range in Insulin-Treated Type 2 Diabetes

Dr. Kiera Booth, MD, is a board-certified dermatologist practicing at Premier Dermatology & Cosmetic Surgery in the Newark and Middletown, Deleware areas.

Credit: Premier Dermatology and Cosmetic Surgery

Hidradenitis Suppurativa (HS) Awareness Week

 draws attention to the challenges faced by patients living with the chronic inflammatory skin condition, Kiera Booth, MD, board-certified dermatologist at Premier Dermatology and Cosmetic Surgery, spoke in an interview with 

 on recent advances shaping HS management.

With an expanding array of biologic therapies and additional treatment options in development, Booth noted that clinicians now have more opportunities than ever to help patients achieve meaningful disease control and improve quality of life. In an interview with 

, Booth highlighted the importance of individualized treatment selection, the growing role of procedural interventions such as deroofing, and the need to address persistent barriers to care, including delayed diagnosis and undertreatment.

She also shared her perspective on emerging therapies, particularly Janus kinase (JAK) inhibitors, and discussed how the evolving therapeutic landscape may continue to improve outcomes for patients with HS in the years ahead. This Q&A interview with Booth highlights each of these points regarding HS:

It is great to be able to speak with leaders in dermatology such as yourself who can speak to hidradenitis suppurativa (HS) and help to raise awareness in honor of HS Awareness Week during the first week of June. How do you currently approach treatment selection for patients with moderate to severe HS?

I think the one of the biggest things when trying to pick medication or treatment for HS is the patient's expectations and what their goals are, how frequently they're having flare-ups, whether they're very severe flare-ups that are infrequently, and that would still be moderate to severe, or they're having very frequent flare-ups but they're just so numerous that it's creating a lot of disease burden.

 What recent therapies or clinical data in HS do you think dermatologists should be paying the closest attention to right now?

I think there have been in the past few years a couple of new medications that have come out, some injectable biologics that are really great options for patients, and an expanded toolbox for providers that make HS so much more fun to treat, because there are just so many more options; we're able to get so many more patients feeling better.

 How would you say the treatment landscape for HS has changed over the last few years?

I think there have been some changes over the past few years with the approval of Bimzelx and Cosentyx, but I think that the treatment landscape is going to just explode over the next few years with the medications that are currently in clinical trials. There are going to be even more options for patients. Also, there has been a lot more discussion and teaching about procedural options for patients. I think a lot more clinicians are getting comfortable with treatments like deroofing, which is just providing the best care for patients when there's the combination of medical and surgical management for HS.

How important is deroofing for clinicians in dermatology when they're approaching HS and HS treatment?

Booth: I think deroofing can be hugely impactful to patients with HS. So often, there's a big delay in diagnosis that we've heard about a lot. Because of that, patients have long-standing tunnels and larger areas, or different areas that continue to come back. It's always the same spot that flares, so deroofing procedures are able to get rid of those areas in a way that minimizes the likelihood of recurrence compared to some of the older surgical techniques with excisions with big grafts or flaps that have a slightly higher chance of having recurrence in that local area.

You touched on the concept of delayed diagnoses. How big of a deal is that in the HS treatment space, and how can we approach it differently? Is it a matter of education?

The delay in diagnosis is huge. I think it's something that has a lot of parts that play into it. There's the delay in getting patients in front of a dermatologist, which often delays diagnosis if they're only going to the ER, and the ER doctor is only treating an acute flare-up. They're not getting the long-term management for this chronic condition, but I think there's also been a delay in getting into some of the advanced therapies. [This is] because they are somewhat newer, and some people, some patients have a hesitancy with the idea of systemic medications or biologics, but getting to treat their disease under control as quickly as possible is so important. [This is] because otherwise you're creating these permanent cysts and tracks and tunnels underneath the skin, and those are going to be there; even if the inflammation gets under control later down the road, there's going to be some amount of scarring or permanent changes made by the chronic inflammation of HS.

When managing moderate to severe age HS, what would you say, generally speaking, are the biggest challenges clinicians still face?

There's no one medication that is perfect for everyone, and there are definitely still patients that are suboptimally controlled on the current treatment options. Also, there are patient limitations for certain medications, and so if patients have Crohn's disease or ulcerative colitis, then they, they can't do one of the IL-17s, and so that really limits their treatment options, but some of the newer medications on the horizon are really exciting.

Looking ahead, what types of treatment strategies or drug targets do you think could have the biggest impact on HS care in the future?

I think for sure the biggest thing that's coming in HS is the JAKs. Having JAK inhibitors in the HS space is going to be great to provide an oral option that's going to be very potent at reducing inflammation, and also some of the options that are that are in the pipeline have multiple indications, and so those will be great for treating those patients with multiple comorbidities. If there's one medication that treats multiple conditions that can be helpful in some patients.

 Do you urge clinicians to make sure to have a conversation about JAK inhibitors with regards to some of the safety concerns related to heart conditions and black box warnings? Do you feel like that's a conversation needing to be had?

It's definitely something that clinicians need to be comfortable with to understand the data and where both where the boxed warnings came from and also how they relate to the current medications and the current patients. [This is] both for themselves to feel comfortable prescribing the medication and then to be able to explain this to patients, because it's very nuanced…I think there is more and more evidence that the initial trials that led up to the boxed warnings were maybe related to such a different patient population, it doesn't translate well. Also, each individual state has its own set of systemic risk factors associated with it, and having any chronic inflammatory condition is going to put you at risk for other comorbidities outside of the skin. How that relates to a medication is both positive and negative. Decreasing systemic inflammation in the skin can help with other comorbidities, or the medications can have side effects.

 What do you hope clinicians walk away with for HS Awareness Week, and what do you hope they spread the word about regarding HS management?

For HS awareness week, I'm hopeful that clinicians will feel engaged and empowered to treat HS patients. These are patients that have been suffering often for a very long time, and often in private that, and so it's something that is so impactful and can really change their lives. As I said, it's there are several options now. It's soon to be lots of options, and treating HS now is so different than it was 10 years ago. When we were there, there was nothing you could do to help these people. It felt horrible. It was a long visit. It was a hard visit. Nobody got results that they wanted. Now there's really great options for medications that are safe and effective and get patients so much better.

Booth had no disclosures of note to highlight.

Krueger JG, Frew J, Wolk K, et al. Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape. Br J Dermatol. 2024 Jan 23;190(2):149-162. 

Ribero S, Dapavo P, Casalegno C; HS Awareness Working Group. Improving the disease awareness: how a communication campaign brings hidradenitis suppurativa to the light. J Eur Acad Dermatol Venereol. 2019 Oct;33 Suppl 6:7-9. 

Management of moderate-to-severe hidradenitis suppurativa is shifting with new biologics and growing comfort with combined medical–procedural strategies. Treatment selection should align with patient goals, flare frequency, and disease burden, while recognizing limitations such as comorbid IBD restricting IL‑17 use. Deroofing can durably address chronic sinus tracts and reduce local recurrence versus wider excisions. Persistent delays in dermatology referral and reluctance toward systemic therapy perpetuate irreversible scarring. Oral JAK inhibitors are anticipated to broaden options, requiring nuanced counseling around boxed-warning safety data.

This Q&A interview highlights key takeaways regarding hidradenitis suppurativa, raising awareness for HS Awareness week, and the current treatment landscape.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Q&A: How Does the Current HS Landscape Look? With Kiera Booth, MD

Ecnoglutide, a cAMP-biased glucagon-like peptide-1 receptor agonist (GLP-1 RA), produced 35% greater weight loss than semaglutide at 20 weeks in a head-to-head randomized trial, according to interim data presented as a late-breaking abstract at the 

 cAMP-biased GLP-1 receptor agonist developed by Sciwind Biosciences; engineered to preferentially activate cAMP signaling while minimizing β-arrestin recruitment and receptor internalization

 Approved by China's National Medical Products Administration for chronic weight management; Pfizer holds exclusive commercialization rights in mainland China

 In 664 Chinese adults with overweight or obesity, the 2.4 mg dose produced 15.4% mean weight loss at 48 weeks, with a 0.6% discontinuation rate due to gastrointestinal adverse events

 Evaluated in the EECOH phase 3 trial series; phase 3 data demonstrate glycemic efficacy and weight loss versus placebo and active comparators in adults with type 2 diabetes on background therapy

Traditional GLP-1 RAs have been used to treat 

 since 2005 and gained approval for weight management in 2014, but individual heterogeneity in glucose-lowering potency and weight reduction efficacy, along with gastrointestinal tolerability concerns, have driven interest in next-generation agents. Biased agonism selectively favoring specific intracellular signaling pathways at a receptor represents one such engineering strategy of these agents.

Ecnoglutide is designed to potently induce cAMP signaling while avoiding GLP-1 receptor internalization, a signaling profile that preclinical data suggest may translate to more pronounced glycemic and weight-loss outcomes versus semaglutide.

“Better weight loss therapies do not come from simple stacking of targets, but from precise regulation of key biological mechanisms. The head-to-head study of ecnoglutide versus semaglutide provides direct clinical evidence for this innovative concept, marking an important milestone in the translation of biased agonist mechanisms from cutting-edge science to clinical application,” Hai Pan, Founder and CEO of Sciwind Biosciences, said in a statement. “From Nobel Prize-level basic research to patient-accessible clinical products, we will remain committed to scientific translation, turning more cutting-edge scientific achievements into tangible health benefits for patients worldwide."

The SLIMMER-UP-SWITCH trial was a multicenter, randomized, open-label phase 2 study conducted at 17 centers in China, enrolling 163 adults with 

 (BMI ≥30 kg/m²).¹ Participants were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous injections of ecnoglutide or semaglutide at the same maintenance dose of 2.4 mg. The pre-specified interim analysis was conducted at week 20 of a 60-week treatment period.

At week 20, the least-squares mean percentage change in body weight from baseline was −12.8% in the ecnoglutide group versus −9.5% in the semaglutide group (

<.0001).¹ The proportion of participants achieving ≥5% weight loss was 99% with ecnoglutide versus 86% with semaglutide (

<.01), and ≥10% weight loss was achieved by 74% versus 40%, respectively (

<.001). Ecnoglutide also produced a 20% greater reduction in waist circumference (10.5 cm vs 8.7 cm; 

<.05), with superior reductions in arm and neck circumference as well.¹

The drug's safety profile in SLIMMER-UP-SWITCH was consistent with prior SLIMMER program data. Its favorable gastrointestinal tolerability is particularly notable because gastrointestinal adverse events are among the primary reasons patients discontinue GLP-1 RA therapy. In the earlier phase 3 SLIMMER obesity trial in 664 adults, the treatment discontinuation rate due to gastrointestinal adverse events was 0.6%.¹

The data arrive as the field weighs increasingly differentiated next-generation incretin strategies. In the phase 3 EECOH-1 trial in type 2 diabetes, ecnoglutide demonstrated pronounced improvements versus placebo in glycemic control and body weight, with a favorable safety and tolerability profile, supporting its potential as a treatment option for type 2 diabetes.

Ecnoglutide is currently approved by China's National Medical Products Administration for chronic weight management, with Pfizer holding exclusive commercialization rights in mainland China. No US regulatory submission has been announced for the obesity indication. The 60-week SLIMMER-UP-SWITCH trial remains ongoing.

"These new findings add to the clinical evidence that new generation biased GLP-1 therapies in weight management and metabolic treatment can offer patients enhanced efficacy, tolerability and safety,” said Jean-Christophe Pointeau, Global Senior Vice President and President of Pfizer China.

Sciwind Biosciences Co., Ltd. Head-to-head study validates the clinical advantage of new-generation biased GLP-1: ecnoglutide delivers 35% greater weight loss than semaglutide. Published June 7, 2026. Accessed June 7, 2026. 

https://www.prnewswire.com/news-releases/head-to-head-study-validates-the-clinical-advantage-of-new-generation-biased-glp-1-ecnoglutide-delivers-35-greater-weight-loss-than-semaglutide-302793395.html

Ji L, et al. Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity. 

Guo W, et al. Discovery of ecnoglutide — a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog. 

https://doi.org/10.1016/j.biopha.2023.115148

El Eid L, et al. Biased agonism and polymorphic variation at the GLP-1 receptor: implications for the development of personalised therapeutics. 

Interim week-20 data from the phase 2, open-label SLIMMER-UP-SWITCH trial in 163 adults with obesity showed ecnoglutide, a cAMP-biased GLP-1 RA engineered to limit receptor internalization, outperforming semaglutide 2.4 mg weekly. Least-squares mean weight change was −12.8% versus −9.5% (P<.0001), with higher rates of ≥5% and ≥10% loss and greater waist reduction. Gastrointestinal tolerability remained favorable, aligning with low GI-driven discontinuation in prior phase 3 data. China approval and Pfizer commercialization rights are in place; 60-week follow-up continues.

In the phase 2 SLIMMER-UP-SWITCH trial, ecnoglutide delivered greater weight loss and waist circumference reduction than semaglutide at 20 weeks in adults with obesity in China.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Ecnoglutide Delivers 35% Greater Weight Loss Than Semaglutide in Head-to-Head Trial

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Trang Ly, PhD, MBBS, is the senior vice president and Chief Medical Officer at Insulet.

Diabetes Dialogue: Omnipod and AID Advancements at Insulet, With Trang Ly, PhD, MBBS

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

In this special episode recorded live at the American Diabetes Association (ADA) Scientific Sessions 2026 in New Orleans, Louisiana, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, welcome Trang Ly, PhD, MBBS, senior vice president and Chief Medical Officer at Insulet, to discuss the continued evolution of automated insulin delivery (AID) technology and emerging developments across the Omnipod platform.

To begin the episode, Ly first reviews updates to Omnipod 5, focusing on enhancements aimed at increasing time in automated mode and improving glucose management. She explains that user feedback identified opportunities to support lower glucose targets and reduce interruptions related to system alerts. Data from real-world evidence and computer simulations suggest that lowering the glucose target from 110 to 100 mg/dL may lead to meaningful improvements in time in range and time in tight range without increasing hypoglycemia risk.

The group discusses early clinical experience with these enhancements, including findings from users who transitioned to the updated system. Ly highlights that even a highly engaged population already using lower targets experienced additional improvements, including a 2% increase in time in range and a 5% increase in time in tight range over a short period of use. The conversation emphasizes the importance of making these improvements broadly available rather than waiting for routine follow-up visits, particularly given the potential benefits without additional safety concerns.

The discussion then turns to Omnipod 6, with Ly sharing newly presented clinical trial data evaluating the next-generation system. She describes the study design, which enrolled users already achieving strong glycemic control on Omnipod 5 and assessed whether further intensification through algorithm improvements could safely provide additional benefits. The results demonstrated a 4% improvement in time in range and up to a 7% increase in time in tight range, with particularly notable improvements among individuals with type 1 diabetes aged 14 years and older.

Ly explains that Omnipod 6 builds on previous technology through changes to the core algorithm, allowing the system to deliver more insulin when users do not bolus consistently. The panel explores how this approach may reduce the burden of diabetes management by allowing the algorithm to take on more responsibility while maintaining glycemic control. They discuss the potential psychological benefits of reducing the daily demands placed on people with diabetes, especially as sensor accuracy and automation continue to improve.

The conversation also highlights future opportunities for AID in type 2 diabetes. Ly shares early feasibility data from a fully closed-loop system designed specifically for individuals with type 2 diabetes, emphasizing its simplified approach without requiring traditional pump programming or meal bolusing. In this study, participants experienced improvements in time in range, demonstrating the potential for automated insulin delivery to reach broader populations.

Isaacs and Bellini discuss the need to reconsider barriers to insulin pump adoption in type 2 diabetes and recognize AID as an accessible option for patients who may benefit. Ly emphasizes that technology should support people across different levels of engagement, offering both highly customizable systems for those seeking intensive management and simpler automated approaches for those looking to reduce daily treatment demands.

The episode concludes with a discussion of the future of diabetes technology, including improved connectivity, expanded device flexibility, and continued integration with complementary therapies such as GLP-1 receptor agonists. Ly underscores that innovation should not only improve clinical outcomes but also reduce the burden of care, allowing people with diabetes to spend less time managing their condition and more time living their lives.

Editors’ Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others. Ly reports a disclosure with Insulet.

Insulet. Insulet Reveals New Data Supporting Breakthrough Omnipod 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care. June 6, 2026. Accessed June 7, 2026. 

https://investors.insulet.com/news/news-details/2026/Insulet-Reveals-New-Data-Supporting-Breakthrough-Omnipod-6-and-Fully-Closed-Loop-AID-Systems-Designed-to-Improve-Outcomes-Reduce-Effort-and-Unlock-Barriers-to-Care/default.aspx

Podcasts

Trang Ly, PhD, MBBS, joins the show to discuss Insulet’s recent advancements in automated insulin delivery and the trajectory of the Omnipod platform.

Type 1 Diabetes

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

DKA remains a growing challenge in diabetes care, with new data highlighting missed diagnoses, rising admissions, and higher costs.

Despite Advances, Gaps in DKA Recognition Persist Across Diabetes Populations

Stay updated with the latest healthcare breakthroughs, including FDA regulatory decisions, phase 3 data, and new clinical guidelines.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

The HCPFive: Top News for Healthcare Providers from the Week of 05/31

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

A new substudy of VESALIUS-CV presented at ADA 2026 has confirmed that evolocumab’s cardioprotective effects extend to patients at risk from diabetes.

VESALIUS-CV: Evolocumab Reduces Cardiovascular Events in Patients With High-Risk Diabetes

Across a trio of phase 3 trials, CagriSema delivered superior HbA1c reduction and weight loss versus semaglutide in adults with type 2 diabetes

CagriSema Outperforms Semaglutide Alone Across Phase 3 REIMAGINE Trials

Vivian Fonseca, MD, is professor of medicine, assistant dean for clinical research, and the Tullis-Tulane Alumni Chair in Diabetes at Tulane University School of Medicine.

Vivian Fonseca, MD, explains data showing nearly half of patients with T2D discontinued GLP-1 therapy within 1 year, reducing their likelihood of achieving weight loss and HbA1c goals.

GLP-1 Discontinuation Cuts Chances of Meeting Weight Loss, Glycemic Goals in T2D

Timothy Garvey, MD, is a professor of medicine at the Univeristy of Alabama at Birmingham. 

Timothy Garvey, MD, discusses petrelintide’s efficacy in patients with overweight and obesity, as well as its comparably low incidence of gastrointestinal effects.

ZUPREME-1: Petrelintide Reduces Obesity, Maintains Tolerability in Phase 2 Trial

Orforglipron added to titrated insulin glargine reduced HbA1c by up to 2.05% and body weight by up to 6.1% versus placebo, without increasing hypoglycemia risk.

ACHIEVE-5: Orforglipron Improves Glycemic Control, Weight in T2D on Basal Insulin

Carel le Roux, PhD, MSC, is a director of the Metabolic Medicine Group at the University College of Dublin School of Medicine.

Carel le Roux, PhD, discusses the full results from SYNCHRONIZE-1, a trial investigating Boehringer Ingelheim’s dual GLP-1/glucagon agonist.

Survodutide Shows Fat Mass Loss, Liver Fat Reductions in Patients With Obesity Without T2D

In a post-hoc analysis of ATTAIN-1 and ATTAIN-2, the highest dose of orforglipron delivered meaningful weight loss across all menopause stages.

Orforglipron Delivers Significant Weight Loss At Every Stage of Menopause in Phase 3 ATTAIN Trials

Shah explains proactive ketone monitoring, home DKA prevention strategies, and the future of continuous ketone monitoring.

Latest News

Tezepelumab Reduces Severe Asthma Exacerbations by 70% in Phase 4 PASSAGE

twiist AID System Improves HbA1c, Time in Range in Insulin-Treated Type 2 Diabetes

Q&A: How Does the Current HS Landscape Look? With Kiera Booth, MD

Ecnoglutide Delivers 35% Greater Weight Loss Than Semaglutide in Head-to-Head Trial

Diabetes Dialogue: Omnipod and AID Advancements at Insulet, With Trang Ly, PhD, MBBS